Loading...
Market
Region most impacted by AstraZeneca’s Singapore facility
4
Resolution / Starting Odds
Asia-Pacific • 33%
North America • 33%
Europe • 34%
Market analysis reports, AstraZeneca sales data
Story
AstraZeneca to Build $1.5 Billion Cancer Drug Manufacturing Facility in Singapore
May 20, 2024, 06:51 AM
AstraZeneca is planning to build a $1.5 billion manufacturing facility in Singapore to enhance its portfolio of antibody-drug conjugates (ADCs). This investment aims to bolster the production of a promising category of cancer-killing drugs. The Anglo-Swedish drugmaker announced the plan on Monday, highlighting its commitment to expanding its capabilities in the oncology sector. The move also signals a shift in the drug industry as companies increasingly split from China.
View original story
Similar markets
Oncology • 33%
Biopharmaceuticals • 33%
Rare Diseases • 33%
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
$50 Billion • 25%
$60 Billion • 25%
$70 Billion • 25%
$80 Billion • 25%
Stock price increases • 33%
Stock price decreases • 33%
Stock price remains stable • 34%
Europe • 25%
North America • 25%
Asia • 25%
Rest of the World • 25%
Southeast Asia • 33%
South America • 33%
Central America • 34%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of the World • 25%